Serum Osteopontin Enhances Hepatocellular Carcinoma Diagnosis and Predicts Anti-PD-L1 Immunotherapy Benefit
Serum OPN demonstrates standalone diagnostic value for HCC and enhances conventional biomarker panels when combined with AFP and AST. OPN high pattern identify patients likely to benefit from anti-PD-L1 immunotherapy, suggesting its dual utility as a diagnostic and predictive biomarker.
Authors
- Yingqi Pi
- Shuangba He (ORCID: https://orcid.org/0000-0002-5171-8819)
- Shulin Chen (ORCID: https://orcid.org/0000-0002-0280-1536)
- Fei Zou (ORCID: https://orcid.org/0000-0002-6637-3593)
- Yiling Song
- Linfang Li (ORCID: https://orcid.org/0000-0002-2336-9885)
- Miantao Wu (ORCID: https://orcid.org/0000-0001-7949-6755)
Institutions
- Sun Yat-sen University (CN)
- The Seventh Affiliated Hospital of Sun Yat-sen University (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Sun Yat-sen University Cancer Center (CN)
- Chongqing Medical and Pharmaceutical College (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Journal of Hepatocellular Carcinoma
- Published
- 2025-04-01
- DOI
- https://doi.org/10.2147/jhc.s514144
- Citations
- 2
- Primary Topic
- Bone and Dental Protein Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.34